Sentiment Change Report: Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Sentiment for Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) institutional sentiment increased to 1.37 in 2019 Q1. Its up 0.30, from 1.07 in 2018Q4. The ratio is more positive, as 74 investment managers increased or started new holdings, while 54 sold and reduced holdings in Ironwood Pharmaceuticals Inc. The investment managers in our partner’s database reported: 146.70 million shares, up from 140.64 million shares in 2018Q4. Also, the number of investment managers holding Ironwood Pharmaceuticals Inc in their top 10 holdings increased from 2 to 3 for an increase of 1. Sold All: 16 Reduced: 38 Increased: 44 New Position: 30.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.40 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

The stock decreased 1.64% or $0.15 during the last trading session, reaching $8.97. About 1.27M shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 32.56% since August 15, 2018 and is downtrending. It has underperformed by 32.56% the S&P500.

Sarissa Capital Management Lp holds 15.36% of its portfolio in Ironwood Pharmaceuticals, Inc. for 7.54 million shares. Ecor1 Capital Llc owns 4.40 million shares or 5.48% of their US portfolio. Moreover, Bridger Management Llc has 4.48% invested in the company for 4.18 million shares. The Maryland-based Brown Capital Management Llc has invested 1.41% in the stock. Broderick Brian C, a Massachusetts-based fund reported 329,233 shares.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Ratings analysis reveals 25% of Ironwood Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Ironwood Pharma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $13 while the high is $18. The stock’s average target of $15.25 is 70.01% above today’s ($8.97) share price. IRWD was included in 8 notes of analysts from February 22, 2019. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, March 27. Credit Suisse maintained the shares of IRWD in report on Friday, March 22 with “Hold” rating. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Friday, February 22. Mizuho has “Buy” rating and $18 target. H.C. Wainwright upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, February 25. H.C. Wainwright has “Neutral” rating and $14 target. H.C. Wainwright maintained it with “Hold” rating and $13 target in Monday, June 24 report.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Businesswire.com which released: “Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call – Business Wire” on April 18, 2019, also Nasdaq.com with their article: “Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates – Nasdaq” published on July 31, 2019, Seekingalpha.com published: “Ironwood completes Cyclerion spin-off – Seeking Alpha” on April 01, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Seekingalpha.com and their article: “Ironwood Pharmaceuticals (IRWD) Presents At 37th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” published on January 10, 2019 as well as Finance.Yahoo.com‘s news article titled: “Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ? – Yahoo Finance” with publication date: May 02, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.